Low frequency of disease flare in patients with rheumatic musculoskeletal diseases who received SARS-CoV-2 mRNA vaccine.

Francesca Romana SpinelliEnnio Giulio FavalliCristina GarufiMartina CornalbaSerena ColafrancescoFabrizio ContiRoberto Caporali

Published in: Arthritis research & therapy (2022)

The low incidence rate of disease reactivation and the similar AEFI occurrence compared to controls should reassure on mRNA vaccine safety in RMD patients.

Keyphrases

sars cov
end stage renal disease
newly diagnosed
chronic kidney disease
ejection fraction
rheumatoid arthritis
risk assessment
prognostic factors
risk factors
peritoneal dialysis
respiratory syndrome coronavirus
patient reported outcomes
patient reported